A Comprehensive Evaluation of the Antibody-Verified Status of Eplets Listed in the HLA Epitope Registry

• Published in: Frontiers in immunology Vol. 12; p. 800946
• Main Authors: Bezstarosti, Suzanne, Bakker, Kim H, Kramer, Cynthia S M, de Fijter, Johan W, Reinders, Marlies E J, Mulder, Arend, Claas, Frans H J, Heidt, Sebastiaan
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 28-01-2022
• Subjects: Alleles; Amino Acid Sequence; Antibodies, Monoclonal - immunology; antibody verification; Databases, Genetic; epitope-matching; Epitopes - chemistry; Epitopes - genetics; Epitopes - immunology; eplet; Histocompatibility - genetics; Histocompatibility - immunology; Histocompatibility Testing; HLA Antigens - chemistry; HLA Antigens - genetics; HLA Antigens - immunology; human leukocyte antigen; Humans; Immunology; Isoantibodies - immunology; Models, Molecular; reactivity pattern; Registries; Structure-Activity Relationship; Transplantation; eplet; human leukocyte antigen; epitope-matching; reactivity pattern; transplantation; antibody verification; monoclonal antibody
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2021.800946

Matching strategies based on HLA eplets instead of HLA antigens in solid organ transplantation may not only increase the donor pool for highly sensitized patients, but also decrease the incidence of
donor-specific antibody formation. However, since not all eplets are equally capable of inducing an immune response, antibody verification is needed to confirm their ability to be bound by antibodies, such that only clinically relevant eplets are considered. The HLA Epitope Registry has documented all theoretically defined HLA eplets along with their antibody verification status and has been the foundation for many clinical studies investigating eplet mismatch in transplantation. The verification methods for eplets in the Registry range from polyclonal sera from multi- and uni-parous women to murine and human monoclonal antibodies (mAbs), and antibodies purified by adsorption and elution from sera of HLA immunized individuals. The classification of antibody verification based on different methods for validation is problematic, since not all approaches represent the same level of evidence. In this study, we introduce a classification system to evaluate the level of evidence for the antibody-verified status of all eplets in the HLA Epitope Registry. We demonstrate that for a considerable number of eplets, the antibody-verified status is solely based on polyclonal serum reactivity of multiparous women or on reactivity of murine mAbs. Furthermore, we noted that a substantial proportion of patient sera analyses and human mAb data presented in the HLA Epitope Registry Database has never been published in a peer-reviewed journal. Therefore, we tested several unpublished human HLA-specific mAbs by luminex single antigen beads assay to analyze their HLA reactivity for eplet antibody verification. Although the majority of analyzed mAbs indeed verified their assigned eplets, this was not the case for a number of eplets. This comprehensive overview of evidence for antibody verification of eplets in the HLA Epitope Registry is instrumental for future investigations towards eplet immunogenicity and clinical studies considering antibody-verified eplet mismatch in transplantation and warrants further standardization of antibody verification using high quality data.